JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 35 No. 8 1274-1278
© 1994 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bisi, G.
Right arrow Articles by Fazzini, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bisi, G.
Right arrow Articles by Fazzini, P. F.

Sublingual Isosorbide Dinitrate to Improve Technetium-99m-Teboroxime Perfusion Defect Reversibility

Gianni Bisi, Roberto Sciagrà, Giovanni M. Santoro, Francesca Zerauschek and Pier Filippo Fazzini

Nuclear Medicine Unit, Department of Clinical Pathophysiology, University of Florence
Division of Cardiology, Careggi Hospital, Florence, Italy

Correspondence: For correspondence and reprints contact: Gianni Bisi, MD, Nuclear Medicine Unit, Department of Clinical Pathophysiology, University of Florence, Viale Morgagni 85, I-50134 Florence, Italy.

ABSTRACT

Previous studies demonstrate perfusion defect reversibility in 201Tl reinjection imaging performed after the administration of nitrates. This study tests whether the acute sublingual administration of isosorbide dinitrate (ISDN) could improve the capability of 99mTc-teboroxime to detect reversibility in exercise-induced perfusion defects. Methods: Ten patients with previous myocardial infarction underwent exercise, redistribution and reinjection 201Tl imaging, 99mTc-teboroxime exercise and rest scans. Following the latter, 5 mg sublingual ISDN were given, 99mTc-teboroxime was reinjected and images collected. Results: The total defect score/patient in the 201Tl images was 10.5 ± 3.1 (mean ± s.d.), decreasing to 7.4 ± 2.7 after redistribution (p < 0.02) and to 4.8 ± 2.1 after reinjection (p < 0.01 versus redistribution). The total defect score in 99mTc-teboroxime exercise images was 12.7 ± 3.1 (p < 0.05 versus 201Tl exercise), decreasing to 7.3 ± 3.3 at rest (p < 0.01 versus exercise, NS versus 201Tl redistribution) and to 5.6 ± 2.6 in ISDN images (p < 0.02 versus rest, p < 0.05 versus 201Tl redistribution, NS versus reinjection). Of the 44 abnormal segments in 201Tl exercise images, the redistribution scan identified 26 defects as reversible and 18 as fixed. After reinjection, 37 defects appeared reversible and only seven fixed (p < 0.005 versus redistribution). Stress-rest 99mTc-teboroxime classified 33 segments as reversible and 11 as fixed (NS versus both 201Tl protocols). After ISDN, the uptake score increased in 19 segments. Therefore, 37 were classified as reversible and seven as fixed defects (p < 0.01 versus 201Tl redistribution, NS versus 201Tl reinjection). Conclusions: Sublingual ISDN before 99mTc-teboroxime rest injection seemed to improve the tracer capability of detecting reversibility in exercise-induced perfusion defects.

Key Words: isosorbide dinitrate • technetium-99m-teboroxime • thallium-201 • myocardial viability




This article has been cited by other articles:


Home page
JNMHome page
R. Sciagra
Nitrates and Viability: A Durable Affair
J. Nucl. Med., May 1, 2003; 44(5): 752 - 755.
[Full Text] [PDF]


Home page
CirculationHome page
L. Ma, L. Chen, L. Gillam, D. D Waters, and C. Chen
Nitroglycerin Enhances the Ability of Dobutamine Stress Echocardiography to Detect Hibernating Myocardium
Circulation, December 2, 1997; 96(11): 3992 - 4001.
[Abstract] [Full Text]


Home page
CirculationHome page
Z.-X. He, R. Medrano, J. T. Hays, J. J. Mahmarian, and M. S. Verani
Nitroglycerin-Augmented 201Tl Reinjection Enhances Detection of Reversible Myocardial Hypoperfusion : A Randomized, Double-Blind, Parallel, Placebo-Controlled Trial
Circulation, April 1, 1997; 95(7): 1799 - 1805.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1994 by the Society of Nuclear Medicine.